Immix Biopharma, Inc. (IMMX) Stock Price & Analysis
Immix Biopharma, Inc. (IMMX) closed at USD 8.13 on Wednesday, October 28, 2026, up 0.93% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.05; the Oct 28, 2026 session ranged USD 7.88–8.21 on volume of 1,229,694 shares. Market capitalization is $673.59M, with a 52-week range of USD 2.85–15.1 (NCM). Source: Nexqual, retrieved October 29, 2026 at 06:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IMMX.md
Key facts (IMMX)
- Analysts: Buy (mean 1.57 on a 1–5 scale) (7 analysts), mean target USD 24.43 (range 17.4–30).
- Total return with dividends: 1Y +118.4% vs S&P 500 +13.6%; 5Y +103.1% vs S&P 500 +79.8%.
- Next earnings: 2026-11-06, EPS estimate USD -0.19, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (IMMX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M | -$41.8M |
| Net income | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M | -$39.9M |
| EPS (diluted) | -$6.64 | -$0.59 | -$0.89 | -$0.76 | -$0.89 | — |
| Free cash flow | -$1.6M | — | -$11.4M | -$15.8M | -$24.7M | -$39.1M |
| Cash + short-term investments | $17.6M | $13.4M | $17.5M | $17.7M | $100M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (IMMX)
P/B 2.9x · FCF yield -5.80% · Earnings yield -5.93%
Analysts (IMMX)
Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 24.43 (low 17.4, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Needham | Target raised | Buy | $21 → $30 |
| 2026-09-15 | Mizuho | Target raised | Outperform | $15 → $26 |
| 2026-08-11 | Morgan Stanley | Target lowered | Overweight | $20 → $19 |
| 2026-08-10 | HC Wainwright & Co. | Target raised | Buy | $20 → $25 |
| 2026-07-22 | Needham | Initiated | Buy | $21 |
Total return (dividends reinvested) (IMMX)
| 1Y (from 2025-10-29) | 5Y (from 2021-12-13) | |
|---|---|---|
| Total return | +118.4% | +103.1% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +119.0% | +15.7% |
| Volatility (annualized) | 82.6% | 96.1% |
| Max drawdown | -44.9% (Aug 2026→Oct 2026) | -85.0% (Jan 2022→Nov 2022) |
IMMX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.18 | −$0.18 | In line | — |
| — | Quarter ended Mar 31, 2026 | −$0.18 | −$0.21 | Beat +14.3% | — |
| — | Quarter ended Dec 31, 2025 | −$0.28 | −$0.16 | Miss −75.0% | — |
| — | Quarter ended Sep 30, 2025 | −$0.24 | −$0.19 | Miss −26.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
IMMX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | Schedule 13G | BlackRock, Inc.: 5.5% of shares, passive 5%+ holder |
| Sep 30, 2026 | 8-K | Other material event “On September 29, 2026, Immix Biopharma, Inc., a Delaware corporation (the "Company"), entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the "Offering"), an aggregate of 11,363,637 shares of its common stock, par value $0.0001 per share (the "Shares") at a public offering price of $11.00 per Share. The Underwriting Agreement contains customary representations, warranties and…” |
| Sep 29, 2026 | 8-K | Regulation FD disclosure; Other material event “On September 29, 2026, the Company announced an update from the Phase 2 NEXICART-2 clinical trial, including positive results of an 89% (40/45) complete response ("CR") rate across all forty-five relapsed/refractory AL Amyloidosis patients enrolled in the trial, as assessed by an independent review committee. Additionally, all twenty-five of the new relapsed/refractory AL Amyloidosis patients are either in CR or already minimum residual disease ("MRD")- negative. To-date, all patients achieving MRD-negativity…” |
| Aug 14, 2026 | Schedule 13G | Eventide Asset Management, LLC, Finny Kuruvilla, M.D. Ph. D.: 5.6% of shares, passive 5%+ holder |
| Aug 13, 2026 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 14.0% of shares, passive 5%+ holder (amended) |
| Aug 7, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 20, 2026 | 8-K | Other material event “As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Given his short tenure, management believes there is no material effect on the business.” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
IMMX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.19 | $-0.17 | −$0.01 | $0 | 7 |
| Next quarter (ends Dec 2026) | $-0.20 | $-0.19 | −$0.01 | $0 | 7 |
| Current fiscal year (ends Dec 2026) | $-0.72 | $-0.69 | −$0.03 | $0 | 8 |
| Next fiscal year (ends Dec 2027) | $-0.95 | $-0.74 | −$0.21 | $27.9M | 8 |
Key Statistics (as of October 29, 2026 at 06:39 UTC)
| Price | USD 8.13 |
|---|---|
| Change | ▲ 0.93% (up) |
| Previous Close | USD 8.05 |
| Open | USD 7.98 |
| Day Range | USD 7.88 – 8.21 |
| 52-Week Range | USD 2.85 – 15.1 |
| Volume | 1,229,694 shares |
| Market Cap | $673.59M |
| Exchange | NCM |
Technical Analysis (IMMX)
Nexqual's technical model rates IMMX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 06:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.11 (neutral) |
| vs SMA50 | Below (USD 11.24) |
| MACD | -0.83 (negative) |
Analyst Ratings (IMMX)
Wall Street analysts rate IMMX "Buy" based on 7 analysts, with a mean price target of USD 24.43 (range USD 17.4–30), per Nexqual as of October 29, 2026 at 06:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 24.43 |
| High Target | USD 30 |
| Low Target | USD 17.4 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (IMMX)
| Next Earnings Date | 2026-11-06 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.18 ▼ miss |
| 2026-03-31 | USD -0.18 vs est -0.21 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.16 ▼ miss |
| 2025-09-30 | USD -0.24 vs est -0.19 ▼ miss |
Source: Nexqual, October 29, 2026 at 06:39 UTC.
Financials & Fundamentals (IMMX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -34.18% |
| Debt / Equity | 0 |
| Current Ratio | 25.13 |
| Total Cash | $232.11M |
| Total Debt | $1.00M |
Source: Nexqual, October 29, 2026 at 06:39 UTC.
Financial Health Score (IMMX)
Nexqual rates Immix Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $232M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$24M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -17%, ROA -16.7% (last 4 quarters, SEC) |
Ownership (IMMX)
| Insider Ownership | +14.78% |
|---|---|
| Institutional Ownership | +68.33% |
| Shares Outstanding | 82.90M |
| Float | 58.27M |
| Short % of Float | +15.17% |
Source: Nexqual, October 29, 2026 at 06:39 UTC.
Leadership (IMMX)
Immix Biopharma, Inc. is led by Ilya Rachman M.B.A., Co-Founder, CEO, Chief Scientific Officer & Chairman, per Nexqual as of October 29, 2026 at 06:39 UTC.
| Co-Founder, CEO, Chief Scientific Officer & Chairman | Ilya Rachman M.B.A. |
|---|---|
| President, CFO & Director | Gabriel Morris B.A. |
Major Backers & Investors (IMMX)
Notable institutional backers of Immix Biopharma, Inc. include Jupiter Topco LLC, Saturn V Capital Management LP, Eventide Asset Management LLC, according to Nexqual as of October 29, 2026 at 06:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 13.68% |
| Saturn V Capital Management LP | 6.51% |
| Eventide Asset Management LLC | 5.44% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 5.44% |
| Deep Track Capital, Lp | 3.88% |
| Opaleye Management Inc. | 3.28% |
| Millennium Management | 2.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 4.19% |
| BlackRock | 4.18% |
| Vanguard Group | 3.5% |
Source: Nexqual, October 29, 2026 at 06:39 UTC.
From Immix Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Any resulting patents in this family are expected to expire in 2043 (not including any patent term adjustment and patent term extension in the United States and equivalents in foreign countries). also have global exclusive rights to PCT Application No.
- We believe that we have substantial know-how and trade secrets relating to our technology and product candidates. of March 2026, we have global exclusive rights to PCT Application No.
- The global amyloidosis treatment market size was estimated at $5.80 billion in 2024 and is projected to reach $11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033, according to Grand View Research. of March 2026, there are no FDA approved drugs for relapsed/refractory AL Amyloidosis. is a next-generation CAR-T targeting B-cell maturation antigen ("BCMA").
- CAR-T cell therapy is a type of immunotherapy that uses the patient's own immune cells, modified with our proprietary technology, to create NXC-201, which is then introduced into the patient's body.
Partnerships
- The First Amendment includes terms specific to new licensed products and requires an additional upfront license fee of $1.5 million, which has been paid in full as of December 31, 2025, as well as development milestone payments of up to $4.5 million upon the Company's achievement of certain milestones.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt